DealsApr 29, 2026, 04:56 PM
AVR Terminates v2vmedtech Agreement; Pays $400K Break Fee
AI Summary
Anteris Technologies Global Corp. (AVR), through its subsidiary, notified v2vmedtech, inc. (v2v) of its decision to discontinue additional development contributions under their April 18, 2023 agreement. This termination, occurring during Stage 2 of the program, requires AVR to pay a $400,000 break fee to v2v. As a result, AVR has no further development obligations, and v2v's initial shareholders can either acquire AVR's equity interest in v2v or reduce AVR's ownership. AVR does not anticipate a material adverse effect on its financial position or liquidity.
Key Highlights
- Anteris Technologies Global Corp. (AVR) terminated its Contribution and Stock Purchase Agreement with v2vmedtech, inc. (v2v).
- The termination occurred during Stage 2 of the development program.
- AVR is required to pay a $400,000 break fee to v2v for continued technology development.
- AVR has no further development contribution obligations under the Agreement.
- v2v's initial shareholders have the option to acquire AVR's equity interest or reduce AVR's ownership.
- The Development Agreement between the companies will also terminate upon payment of the break fee.
- AVR does not expect a material adverse effect on its consolidated financial position or liquidity.
Price Impact
More from AVR